Viewing nowCombinationLiraglutide Duo Tablet 2.5/850 mg (Linagliptin Besylate, Metformin Hydrochloride)
Linagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.

MFDS item code 202401041 · Approved 2024.04.30
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes who are taking both Linagliptin and Metformin. It can be more effective when combined with dietary management and exercise therapy, aiding in the stable management of blood sugar levels. Regular intake can greatly assist in managing diabetes.
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current dose of metformin (for example, a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current dose of metformin. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current dose of metformin. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). Studies evaluating the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is used to control blood sugar and works with the active ingredients Linagliptin and Metformin. This medication should not be given to certain patients, for example, those who are allergic to any ingredients of this medication, have type 1 diabetes, lactic acidosis, diabetic ketoacidosis, or severe renal impairment. In addition, it should not be used in cases of dehydration, severe infections, heart failure, liver dysfunction, acute alcohol intoxication, or in pregnant or breastfeeding women. When using this medication, hypoglycemic symptoms may occur, so it is essential to monitor blood sugar levels frequently, especially when taken with insulin or sulfonylureas. Patients with reduced kidney function should have their renal function monitored regularly through blood tests and should not take this medication if their kidney function is severely impaired. Patients with compromised heart function should also exercise caution when using this medication and regularly monitor their heart and kidney status. If undergoing radiation examinations involving iodine contrasts, the use of this medication should be temporarily stopped before and after the examination until kidney function is restored. Patients undergoing surgery should discontinue use of this medication 48 hours prior to surgery and can resume after kidney function has returned to normal after the procedure. While taking this medication, rare side effects such as acute pancreatitis or blistering dermatitis resembling pemphigus may occur, so if abdominal pain or skin abnormalities present, consult a doctor immediately. The Metformin component can lower vitamin B12 levels, so it's recommended to regularly check vitamin B12 levels during long-term use. It is advised not to use this medication during pregnancy or while breastfeeding. Children under 10 years of age should not use it, as safety and efficacy have not been established. Elderly patients may experience reduced kidney function, thus dosage should be adjusted and kidney function should be regularly tested. In case of overdose, severe side effects such as lactic acidosis can occur, requiring immediate medical treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that blocks out air and moisture, ideally at room temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness.
Orange, biconvex, oval film-coated tablets
30 tablets/bottle, 60 tablets/bottle - 30 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle - 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
DaiWoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
CombinationLinagliptin Besylate 3.34mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Mothers Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.